Alpha-Emitting Radionuclides: Current Status and Future Perspectives-Reference-Cited by-同舟云学术

Alpha-Emitting Radionuclides: Current Status and Future Perspectives

Published:2024-01-08 Issue:1 Volume:17 Page:76
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

Miederer Matthias¹²³⁴^ORCID,Benešová-Schäfer Martina⁵,Mamat Constantin⁶⁷^ORCID,Kästner David⁸,Pretze Marc⁸^ORCID,Michler Enrico⁸,Brogsitter Claudia⁸,Kotzerke Jörg²⁸,Kopka Klaus⁶⁷⁹¹⁰^ORCID,Scheinberg David A.¹¹,McDevitt Michael R.¹²¹³

Affiliation:

1. Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC), 01307 Dresden, Germany

2. Medizinische Fakultät and University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany

3. German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

4. Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany

5. Research Group Molecular Biology of Systemic Radiotherapy, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany

6. Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstr, 400, 01328 Dresden, Germany

7. School of Science, Faculty of Chemistry and Food Chemistry, Technische Universität Dresden, 01062 Dresden, Germany

8. Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany

9. National Center for Tumor Diseases (NCT) Dresden, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307 Dresden, Germany

10. German Cancer Consortium (DKTK), Partner Site Dresden, Fetscherstraße 74, 01307 Dresden, Germany

11. Molecular Pharmacology Program, Sloan Kettering Institute, New York, NY 10065, USA

12. Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA

13. Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA

Abstract

The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.

Publisher

MDPI AG

Link

https://www.mdpi.com/1424-8247/17/1/76/pdf

Reference103 articles.

1. Chan, H.S., de Blois, E., Morgenstern, A., Bruchertseifer, F., de Jong, M., Breeman, W., and Konijnenberg, M. (2017). In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy. PLoS ONE, 12.

2. Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M.M., Huelsenbeck, J., and Schreckenberger, M. (2014). DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS ONE, 9.

3. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates;Miederer;J. Nucl. Med.,2004

4. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications;Miederer;Adv. Drug Deliv. Rev.,2008

5. Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences;Robertson;Curr. Radiopharm.,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scalability study on [133La]LaCl3 production with a focus on potential clinical applications;EJNMMI Radiopharmacy and Chemistry;2024-08-15

2. Advances in targeted alpha therapy of cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-02-20